Boceprevir
A direct-acting antiviral that inhibits the NS3/4A protease enzyme of the hepatitis C virus, blocking viral replication. It was used as part of triple therapy for chronic hepatitis C genotype 1 infection. It has been largely replaced by newer, more effective and better-tolerated all-oral direct-acting antiviral regimens.
Masse moléculaire
519,7000 g/mol
LogP
3,10
TPSA
151,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Inhibits viral protease enzymes required for the cleavage of polyprotein precursors into functional viral proteins, blocking viral maturation and replication.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits viral protease enzymes required for the cleavage of polyprotein precursors into functional viral proteins, blocking viral maturation and replication.
Structure 2D
Cite this structure
Embed this structure
SMILES
CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
InChI
InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
Molecular Formula
C27H45N5O5
HBD / HBA
4 / 5
Liaisons Rotatives
10
Atomes Lourds
37
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A direct-acting antiviral that inhibits the NS3/4A protease enzyme of the hepatitis C virus, blocking viral replication. It was used as part of triple therapy for chronic hepatitis C genotype 1 infection. It has been largely replaced by newer, more effective and better-tolerated all-oral direct-acting antiviral regimens.
Inhibits viral protease enzymes required for the cleavage of polyprotein precursors into functional viral proteins, blocking viral maturation and replication.
Yes, Boceprevir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL218394. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 10324367. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="boceprevir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/boceprevir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/boceprevir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/boceprevir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="boceprevir"></drugfyi-drug>